George Papadopoulos (@Emerald_CG) header
George Papadopoulos (@Emerald_CG) profile picture

Emerald Corporate Group: a consultancy with expertise in market access strategies | healthcare pricing & reimbursement strategies in Australia & Asia Pacific

Sydney, Australia
Joined July 2011
Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)Photo by George Papadopoulos (@Emerald_CG)
Expert Advisory Group on Genomics Australia. The Expert Advisory Group (EAG) on Genomics Australia is providing advice to the #Australian Government through the department on the establishment of a new national genomics body, Genomics Australia. health.gov.au/committees-and… – at Canberra, Australian Capital Territory
1
5
486
George Papadopoulos retweeted
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy nature.com/articles/s41523-0… Exploratory analysis of the phase 3 KEYNOTE-119 trial, which previously showed no overall survival benefit of pembrolizumab over chemotherapy in previously treated metastatic triple-negative #BreastCancer (TNBC), several biomarkers were evaluated for their association with clinical outcomes. Higher levels of tumor-infiltrating lymphocytes (TILs) and a higher T-cell–inflamed gene expression profile (TcellinfGEP) correlated with improved objective response rate, progression-free survival, and overall survival in patients treated with pembrolizumab, but not with chemotherapy. Additionally, patients with a tumor mutational burden (TMB) ≥10 mutations per megabase showed a trend toward greater pembrolizumab benefit, while BRCA1/2 mutation and homologous recombination deficiency status were not predictive of response. Results suggest that TILs, TcellinfGEP, and TMB may serve as biomarkers of pembrolizumab benefit in metastatic TNBC. @JavierCortesMD @ProfAnthoG @LauraTe96206949 @Prof_Nadia_H @LoiSher @KarantzaValia @DrEricWiner
10
1
26
4,574
George Papadopoulos retweeted
One page takeaway/summary on @FDAOncology approval for Atezo + Lurbinectedin based off IMForte on October 2, 2025 and our discussion w/ @StephenVLiu @ipreeshagul and @LealTiciana on Extensive stage small cell lung cancer! #OncTwitter #MedTwitter #lcsm @OncUpdates
Lurbinectedin is now approved in 1L for ES-SCLC based off #IMForte! We had a chance to discuss the trial, findings, AE's and management w/ @ipreeshagul @StephenVLiu & @LealTiciana Full 🗣️: ⭐️ oncbrothers.com/lurbi-approv… ⭐️ On “Oncology Brothers” podcast #OncTwitter #lcsm
1
15
40
7,586
This week in #ProstateCancer in the🚨Weekly RoundUp 🧬 Prostate Cancer Germline Testing: (PROGRESS Registry)
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Sept 26-Oct 2, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe… Discussing: 🫁 #LungCancer/ Immunotherapy ✅Dual CTLA-4 + PD-L1/PD-1 Blockade Shows No OS Advantage Overall but Boosts Outcomes in PD-L1–Low & STK11-Mutant NSCLC ✅Neoadjuvant/Perioperative Immunotherapy Outperforms Adjuvant in Resectable NSCLC, Even in PD-L1–Negative and Squamous Tumors 🩺 #BreastCancer ✅Trastuzumab Deruxtecan Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer (DESTINY-Breast05) NEWS FROM INDUSTRY ✅Adjuvant Ribociclib + Aromatase Inhibitor Maintains 4-Year iDFS Benefit in HR+/HER2– Early Breast Cancer (NATALEE Trial) ✅Sacituzumab Govitecan: Effective for Advanced TNBC & HR+/HER2– Breast Cancer With Practical AE Management Strategies ✅Higher BMI Amplifies Postmenopausal Breast Cancer Risk—Especially in Women With Cardiovascular Disease GI / #GastricCancer ✅Early-Onset Transient Gastritis Common With First-Line Zolbetuximab in CLDN18.2+ Gastric Cancer ✅CLDN18.2 Expression in Gastric Cancer Is Dynamic During Chemoimmunotherapy, Linked to Immune-Inflamed Stroma and Outcomes 🧬 GU / #ProstateCancer ✅Prostate Cancer Germline Testing: Phone or Physician Counseling Boosts Satisfaction; Asian American Men Report Lower Satisfaction (PROGRESS Registry) 🧠 Mental Health / Survivorship ✅Cancer Survivors Use Antidepressants and Anxiolytics More Than Noncancer Peers—With Persistent Racial and Insurance Disparities 🧠 Gyn / #EndometrialCancer ✅“Aggressive” Histology Predicts Prognosis in Surgically Staged, Clinically Uterine-Confined Endometrial Carcinoma @DiFedericoMD @doctordegio @StephenVLiu @bmassutis @faiska_hsk_skt @ErikaHamilton9 @DrSAHaddad @AlexisLeVee @ArmandOrlandi @jamecancerdoc @JAMAOnc @DrRishabhOnco @Onco_Cifu88 @drlopezgalindo @Dr_ElvinaA @JournalCancer @CACancerJournal @HFreisling @IARCWHO @drjkahn @DraMartinezLago @KoheiShitara @zaidheartsci @JAMANetworkOpen @realbowtiedoc @Duke_TORCHE @leitaomd @ChrisDagherMD @masharii3 @matteolambe @Icro_Meattini @hoperugo
1
3
6
1,226
George Papadopoulos retweeted
#Myeloma Paper of the Day: AURIGA subgroup analysis finds dara/len maint in NDMM -> higher MRD (10-5) conversion @ 12 mos in original high-risk (31.8 vs 6.7%), revised (43.8 vs 13.3%) & modified IMS 2024 (41.2 vs 0%) & ultra-high-risk (54.5 vs 0%): pubmed.ncbi.nlm.nih.gov/4105…. #mmsm
2
10
1
29
2,797
George Papadopoulos retweeted
“Can surgery still matter in metastatic prostate cancer?” 🩺 💥 RAMPP trial says maybe yes - even in low-volume mHSPC. 🧪 Design: De novo low-volume mHSPC (≤5 bone mets ± nodes) 👥 Fit for RP + systemic therapy (ADT ± ARPI) 🆚 Radical prostatectomy (RP) + BST vs BST alone 🎯 Primary: Cancer-specific mortality (CSM) 📊 Results (~5 yrs): •🩸 CSM: 13% vs 23% → HR 0.39, p=0.045 ✅ •🧭 Progression: 59% vs 60% (NS) •💀 OS: 81% vs 74% (p=0.13) •⚙️ Complications ≥ G3: 14%, no peri-op deaths 💬 Takeaway: RP added to BST reduced CSM in low-volume mHSPC — mirroring the STAMPEDE RT signal 🔁 But OS gain unproven → discuss in MDT before adopting. 📖 Graefen et al. European Urology 2025. 🔗DOI: doi.org/10.1016/j.eururo.202… #OncoTwitter #ProstateCancer #mHSPC #UroOnc @OncoAlert @myESMO @ESMO_Open @ASCO @EuropeanUrology @EUplatinum @Uroweb
6
43
102
9,632
George Papadopoulos retweeted
Let’s Unite to Fight Cancer! 💪 Ten years ago, we made history with Australia’s first-ever Lutetium-PSMA treatment - research that’s changed prostate cancer care worldwide. Since then, our team has led 10+ clinical trials, bringing cutting-edge science straight to patients and giving men with advanced prostate cancer new hope. Your support keeps this momentum alive. Together, we can drive the next decade of breakthroughs. 👉 Join me and be part of the movement that saves lives: unitetofightcancer.org/micha… – at Melbourne, Victoria
12
1
39
3,283
George Papadopoulos retweeted
⁶⁸Ga-RAYZ-8009 was well tolerated and showed a favorable biodistribution and dosimetry in patients with HCCs, offering promising imaging characteristics. ow.ly/ZCgN50X6X0y #NuclearMedicine #HCC @JuliaBroschLenz
1
3
14
683
George Papadopoulos retweeted
Health economics & outcomes research (#HEOR) doesn’t have to be complex. Join our virtual short course Oct 13–16 to gain practical skills in study design, cost analysis & economic evaluation. Perfect for clinicians & new researchers. Register here: ow.ly/G7n650X4y2i
3
1
5
265
George Papadopoulos retweeted
ESMO 2024 Quick Take Insights: Prostate Cancer - #ARANOTE: Darolutamide + ADT shows significant rPFS benefits in mHSPC, offering a new treatment without docetaxel. - #PEACE3Study: Radium-223 + enzalutamide in mCRPC enhances rPFS & OS when used with bone protection in patients with bone-only metastases. - #SPLASH: 177Lu-PNT2002 improves rPFS in mCRPC post-ARPI, potentially expanding radioligand therapy options pre-chemotherapy. Exciting steps forward for tailored treatments! 💪 #ESMO24 #mHSPC #mCRPC #ReadNow > bit.ly/48yo9pm @zklaassen_md @RKSayyid
1
17
50
4,554
George Papadopoulos retweeted
EV-P is changing first-line care for advanced urothelial carcinoma. A global survey shows where we still hesitate: neuropathy ≥G2, ECOG-PS ≥3, non-UC >50%. @OncJournal @drenriquegrande @OncoBellmunt @ProfSyedHussain @BourlonMaite @ravikanesvaran @dmukherji @AlisonBirtle @UroDocAsh @OncoAlert @IBCG_BladderCA doi.org/10.1093/oncolo/oyaf3…
2
32
1
95
7,866
George Papadopoulos retweeted
Nuclear medicine is transforming cancer care. During #NuclearMedicineWeek, we’re highlighting how Telix is advancing the field by developing diagnostic imaging and targeted therapies that work together to better see and treat cancer. Our theranostic pipeline is among the most advanced in the industry, focused on areas of critical unmet medical need in urologic oncology, neuro-oncology, hematology and other solid tumors. 🎥 Watch this short video to discover how Telix’s pipeline is advancing innovative treatment options for patients. Do you want to shape the future of nuclear medicine? Explore career opportunities with Telix: telixpharma.com/careers/
2
10
596
Predisposition to prostate cancer and clinical implications in a real-life cohort nature.com/articles/s41431-0… Genetic predisposition is present in 5–10% of #ProstateCancer cases, yet international recommendations for genetic testing remain limited despite its increasing use. This study assessed the impact of germline analysis on prostate cancer management. Retrospective data from patients who underwent oncogenetic counselling between 2018 and 2021 included clinical, tumor, and genomic characteristics. Patients with germline pathogenic variants (PVs) were compared with non-carriers using non-parametric tests. Fourteen of 168 patients (8.3%) carried a PV, mostly in DNA repair genes (13/14), including BRCA1/2 (5 patients); 25 patients (14.9%) had variants of uncertain significance. PV carriers were more likely to present with synchronous metastases (79% vs 43%, p = 0.02) and Gleason scores ≥8 (82% vs 53%, p = 0.11). ATM PVs were significantly enriched compared with a healthy control cohort (odds ratio 32.5 [15.8–67.0], p < 0.05). Three of five patients with BRCA1/2 PVs received DNA repair–targeted therapy. This cohort illustrates the influence of oncogenetic counselling on clinical management, underscores the need to refine referral criteria based on disease stage and Gleason score, highlights ATM as a gene of interest, and emphasizes the importance of clear care pathways for germline and/or somatic testing to optimize therapeutic outcomes. @laconss @SibonyMathilde @PLaurentPuig @TlemsaniCamille @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima
7
1
26
2,660
George Papadopoulos retweeted
🚀 Is 6 cycles of Lutetium-177 PSMA the limit? Definitely not! 💪 Our research in 50+ men with prostate cancer treated beyond 6 cycles shows that re-treatment can further improve outcomes. 📉 PSA ↓ >50% in 40% of patients on re-treatment. 🕒 Median overall survival: an impressive 36 months! 👏 Brilliant presentation by Dr Jasmin Weindler (Nuclear Medicine, University of Cologne) at #EANM25 following her @pros_tic @PeterMacCC attachment 💙 Special thanks to @liz_medhurst , our amazing theranostics nurse specialist, who performed much of the work & @ButeauJames #EANM25 @EANM_NucMed
4
41
1
117
7,340
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy jamanetwork.com/journals/jam… In this phase 2 randomized clinical trial evaluating PSMA-guided intensification of salvage radiotherapy (PSMAiSRT) after radical prostatectomy, 128 patients with biochemical recurrence were randomized to receive either standard-of-care salvage radiotherapy (SRT) or PSMA-PET/CT-guided, lesion-targeted SRT. Over a median follow-up of 37 months, PSMAiSRT significantly improved failure-free survival (HR 0.50, P = .04) and eugonadal failure-free survival (HR 0.45, P = .03), particularly among patients with PSA levels ≥0.3 ng/mL (HR 0.17, P = .01), without increasing toxicity or compromising quality of life. These findings suggest that PSMA-PET–guided SRT enables isotoxic intensification that enhances cancer control compared with standard imaging–based approaches, warranting confirmation in an ongoing phase 3 trial. #ProstateCancer @ColinBelliveau_ @taussky @mbarkati @AcadianRO @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima
20
36
3,438
George Papadopoulos retweeted
As Q4 begins, the oncology community is closely watching the @US_FDA for several key regulatory decisions. Sign up 🔐 to access the full list of decisions to watch and what they could mean for clinical practice: onclive.com/view/q4-2025-10-…
1
4
760
George Papadopoulos retweeted
#ASTRO25 Impact of Pre-Rx PSA Kinetics on OS of PCa Pts Treated w/ 177Lu-PSMA-617 @urotoday @SitemanCenter 📌n=90; PSA50 after 2nd cycle: 41.4%, after last cycle 43.2% 📌mOS: 19.1 months (95% CI 15.7-22.5) 📌mOS PSA50 last cycle vs no: NR vs 17.5 mos; p=0.006 📌mOS PSA50 2nd cycle vs no: NR vs 19.1 mos; p=0.031 📌Rapid PSA ⏬ vs no: NR vs 16.8 mos; p=0.021
3
1
10
1,012
George Papadopoulos retweeted
CART vs Bispecific Antibodies for follicular lymphoma? CART👉better efficacy Bispec👉better safety Epcoritamab+R2 could change the debate with promising efficacy Amazing debate with @AnnaSureda5 at @COSTEMCongress
1
13
61
3,814
George Papadopoulos retweeted
Migraine is more than just a headache - and we’re here to make sure the world understands that. When you become a Migraine Australia member, you help us create change, raise awareness, and support people living with migraine. It’s just $30/year, but it means so much more. 💙
1
20
George Papadopoulos retweeted
Making green nuclear medicine and radiotheranostics real in a developing country. ow.ly/nfb750X0BUy #NuclearMedicine #Theranostics #MedicalImaging
5
7
574